Polomar Health Services Terminates Merger Agreement with Altanine, Inc.
PMHS sits 44% above its 52-week low of $0.065 on light trading volume (0.4× avg).
Summary
Polomar Health Services announced the termination of its merger agreement with Altanine, Inc., ending a key strategic initiative and adding to the company's existing financial challenges.
Key Events · M&A and Partnerships · PMHS
-
Merger Agreement Terminated
Polomar Health Services and Altanine, Inc. mutually agreed to terminate their merger agreement, effective June 12, 2026. This follows a May 15 filing where critical financial and listing conditions for the merger were waived.
-
Patent License Agreement Terminated
The Know How and Patent License Agreement with Pinata Holdings, Inc., a subsidiary of Altanine, was also terminated. Polomar has until September 7, 2026, to dispose of any remaining inventory or products developed under this agreement.
-
Settlement Payment for Claims
Polomar will pay Altanine $36,000 in three equal installments of $12,000 each, due on June 15, July 15, and August 15, 2026, for the mutual release of 'other claims' between the parties.
Analysis · PMHS · Life Sciences
Polomar Health Services has terminated its merger agreement with Altanine, Inc., a significant strategic reversal for a company already facing substantial financial distress, including a going concern warning and a major lawsuit. This termination removes a potential path for the company's future, especially after conditions for the merger were waived just last month.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 40.6% of the 330 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PMHS was trading at $0.09 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $0.07 to $960,000.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.